麻豆女优

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 麻豆女优 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Aug 19 2025

Full Issue

Use Of Over-The-Counter Opill Is High Among First-Time Birth Control Users

When Opill became available a year ago, public health experts anticipated it would benefit women without health insurance and those residing in rural areas. The goal was to boost access to reproductive care. A new study shows that the pill is having its desired effect.

About two years after the US Food and Drug Administration approved the first over-the-counter birth control pill in the United States, a new study suggests that many people who may not have had access to contraception before are now using the over-the-counter option. More than a quarter 鈥 26.2% 鈥 of people now using over-the-counter oral contraceptives were using no modern method of birth control before, according to the study published Monday in the medical journal JAMA Network Open. (Howard, 8/18)

On Barth syndrome 鈥

In a highly unusual move, a small biotech company has disclosed a rejection letter from the Food and Drug Administration in hopes of rallying support for regulatory approval of an ultra-rare disease drug. (Silverman, 8/18)

Gilbert Dryden probably only has enough medication to get him through the end of October, his mother, Madison, figures. Seven-month-old Gilbert has a rare genetic condition called Barth syndrome, one that can have dire consequences, like heart failure, extreme muscle weakness and a dramatically reduced life expectancy. Children who die early often don鈥檛 see their fifth birthday. Two infant deaths were reported within the past week, according to the Barth Syndrome Foundation. (Brock and Edwards, 8/18)

More pharmaceutical news 鈥

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on Friday. Roughly 15 million people 鈥 six percent of adults in the United States 鈥 have metabolic dysfunction-associated steatohepatitis, known as MASH. Rates of the disease are rising. (Blum, 8/18)

A federal judge has thrown out a second case against Abbott Laboratories over the safety of its formula for babies born prematurely 鈥 a decision with potential implications for hundreds of other similar cases. In the case, Maryland woman Keosha Diggs alleged that her son developed a life-threatening intestinal disease called necrotizing enterocolitis (NEC) after being fed specialized cow鈥檚 milk formula made by Abbott. Her son, who was born at 32 weeks gestation, then had to undergo surgery to remove a section of his intestine. (Schencker, 8/18)

When the Food and Drug Administration needs outside guidance, it normally turns to a trusted source: a large roster of expert advisers who are carefully vetted for their independence, credentials and judgment. But increasingly, the agency isn鈥檛 calling them. Instead, FDA Commissioner Marty Makary has launched a series of ad hoc 鈥渆xpert panels鈥 to discuss antidepressants, menopause drugs and other topics with physicians and researchers who often have contrarian views and financial interests in the subjects. (Perrone, 8/18)

A small UK study published last week in Nature Communications found that among a cohort of very low birth weight (VLBW) infants, those who received probiotic supplements had fewer antibiotic-resistance genes (ARGs) and multidrug-resistant (MDR) pathogens in their gut than those who didn't, even when they also received antibiotics. (Dall, 8/18)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 麻豆女优